Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The dual SGLT1/2 inhibitor yielded a 32% reduction in myocardial infarction risk and 34% reduction in stroke risk. It's first SGLT inhibitor to provide a significant reduction in both myocardial ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium ...